XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Current assets    
Cash and cash equivalents $ 41,948,000 $ 42,167,000
Investment in Eton Pharmaceuticals 8,642,000 8,503,000
Accounts receivable, net 5,995,000 4,470,000
Inventories 4,396,000 4,217,000
Prepaid expenses and other current assets 1,334,000 1,305,000
Total current assets 62,315,000 60,662,000
Property, plant and equipment, net 2,968,000 3,141,000
Capitalized software costs, net 1,471,000 1,313,000
Operating lease right-of-use assets 6,847,000 5,935,000
Intangible assets, net 15,415,000 15,813,000
Investment in Melt Pharmaceuticals 8,247,000 11,133,000
Goodwill 332,000 332,000
TOTAL ASSETS 97,595,000 98,329,000
Current liabilities    
Accounts payable and accrued expenses 6,758,000 6,337,000
Accrued payroll and related liabilities 1,948,000 3,089,000
Deferred revenue and customer deposits 23,000 16,000
Current portion of operating lease obligations 445,000 272,000
Current portion of finance lease obligations 8,000 8,000
Total current liabilities 9,182,000 9,722,000
Operating lease obligations, net of current portion 6,823,000 6,012,000
Finance lease obligations, net of current portion 7,000 10,000
Loans payable, net of current portion and unamortized debt discount 71,847,000 71,654,000
TOTAL LIABILITIES 87,859,000 87,398,000
Commitments and contingencies  
STOCKHOLDERS’ EQUITY    
Common stock, $0.001 par value, 50,000,000 shares authorized, 27,031,127 and 26,902,763 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively 27,000 27,000
Additional paid-in capital 107,909,000 106,666,000
Accumulated deficit (97,845,000) (95,407,000)
TOTAL HARROW HEALTH STOCKHOLDERS’ EQUITY 10,091,000 11,286,000
Noncontrolling interests (355,000) (355,000)
TOTAL STOCKHOLDERS’ EQUITY 9,736,000 10,931,000
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 97,595,000 $ 98,329,000